Founder and CEO

Dr. Meretzki has proven operational, management, and leadership abilities in Life Science companies. Former founder, CEO, and CTO of Pluristem Life Systems, Inc. (NASDAQ: PSTI; TASE: PLTR). Dr. Meretzki Holds a Ph.D. in biotechnology from the Technion - Israel Institute of Technology in collaboration with the Weizmann Institute of Science, Israel.

Chief Financial Officer

Mr. Livne has been serving as Chief Financial Officer since 2014. Before joining Bonus BioGroup, Mr. Livne was Chief Financial Officer at Bee Contact Communication Ltd., a publicly-traded company (TASE), and Chief Controller at Dexcel Pharma, a privately held international pharmaceutical company. Mr. Livne holds an MBA in Finance and a BA in Accounting and Economics from The Hebrew University.

VP Research & Development

Dr. Ben-David is in charge of the company’s R&D operations. He is a highly experienced R&D manager who has led the development of all Bonus BioGroup’s products. Dr. Ben David holds a Ph.D. degree in medical sciences from the Technion Faculty of Medicine, and his main field of expertise is adult stem cells. Formerly, Dr. Ben David served as the manager of the Technion Musculoskeletal Tissue Engineering Lab.

VP Regulatory & Clinical Affairs

Dr. Kivity is experienced in the global regulatory and clinical affairs landscape throughout the product's lifecycle, with managerial experience from pharma, biotech, and medical device companies. Dr. Kivity has led the successful submissions to worldwide regulatory authorities (FDA, EMA, MHRA, CFDA, Health Canada, AEMPS, the Israeli Ministry of Health, PMDA). Dr. Kivity holds a Ph.D. and MBA degrees from the Technion, the Israeli Institute of Technology.

VP Quality Assurance

Dr. Chemouny completed her residency in France and served as Pharmacist-in-Charge in Taro Pharmaceuticals before joining Bonus. She has >20 years of experience in aseptic manufacturing, GMP, and Quality Affairs.

VP Business Development

With over 15 years of experience in R&D and translating Next Generation Therapies, Dr. Tomer Bronshtein serves as VP of Business Development at Bonus Biogroup. In this position, he is responsible for identifying and developing opportunities to increase the Company's value for patients, healthcare providers, and strategic partners and for planning and managing the Company's stakeholders' engagement efforts

Head of Development

Dr. Atara Novak is the head of Development at Bonus Biogroup with approximately 15 years of experience in Stem Cells and over 8 years of experience in cell therapy. Dr. Novak earned her Ph.D. from the Department of Medical Sciences at the Technion Faculty of Medicine. As Head of Development, Dr. Novak is responsible for developing biological processes, assays, and methods to transform innovative technologies into cutting-edge products that can change patients' lives.

Head of Reaserch

Dr. Yulia Shandalov Levi is in charge of the company’s R&D operations. He is a highly experienced R&D manager who has led the development of all Bonus BioGroup’s products. Dr. Ben David holds a Ph.D. degree in medical sciences from the Technion Faculty of Medicine, and his main field of expertise is adult stem cells. Formerly, Dr. Ben David served as the manager of the Technion Musculoskeletal Tissue Engineering Lab.

Head of Manufacturing

Daniel has earned his bachelor’s degree in Chemical and Biotechnology Engineering from Ariel University. Before joining Bonus, Daniel served as a Process Engineer in the Upstream Department of Insight Biopharmaceuticals and as an engineer and operator in the production pilot at Steba Biotech, gaining much experience in the operation of bioreactor systems and clean rooms.

Executive Chairman of the Board

Mr. Yossi Rauch served as Chief Economist and Manager of the Economics Department of Leumi PIA, Israel’s largest mutual fund company at the time. Mr. Rauch Holds MBA in Finance & Accounting and Computers & Information Systems from the Tel Aviv University and a BA in Economics and Business Administration from Bar-Ilan University.

Director

Mr. Gil Shapira is the CEO and partner in A.D. Clean Rooms Engineering Ltd., a company specializing in designing, constructing, and validating cleanrooms. Mr. Shapira holds a BSc in Industrial Management.

Director

Mr. Yehuda Reznik served as a partner in the international audit firm Kesselman & Kesselman, PwC Israel, from 1999 until 2014. Mr. Reznik holds a B.A. in accounting and economics from Bar - Ilan University.

Director

Mr. Ariel is the CEO of MILOUOT, a company developing, processing, and marketing agricultural produce. Until 2021, he served as the CEO of Biological Industries, a leading supplier to the life science industry that was recently merged into Sartorius AG. Mr. Ariel holds a B.Sc. degree in mechanical engineering.

Director

Ms. Assays is the General Manager of SISMA (www2.sisma.org.il), a non-profit educational organization, and a former member of the National Petroleum Council, Ministry of Energy, Israel. She holds an MBA degree and a BA degree in economics and criminology.

External Director

Mr. Shafir is a Partner-CEO in the strategic consulting company Yanai Group and Yanai Peleg & Co., an investment banking company. Mr. Shafir studied Enocmincs at the Hebrew University, Jerusalem.

MD

Prof. Rozen is the Head of the Department of Orthopedic Surgery at Ha’Emek Medical Center, Afula. <read more> He is the Founder of the Institute for Bone Repair at Rambam Health Care Campus, Haifa, and the Head of the Department of Orthopedic and Traumatology at Zvulun Medical Center, Haifa. Prof. Rozen is a highly recognized researcher in orthopedics with >90 papers published and a particular interest in non-healing fractures making him highly qualified to lead our orthopedic studies.

 DMD

Dr. Tzur is a senior periodontal surgeon specializing in implant surgery and craniomaxillofacial rehabilitation and is the former Director of the Oral & Maxillofacial Surgery Unit at Assaf Harofeh Medical Center. <read more> He has over 30 years of experience in all aspects of the reconstruction and rehabilitation of hard and soft tissue defects of the oral cavity, jaws, and facial structures. In addition, he is involved in dent-alveolar and orthogenetic surgery, reconstruction of disease and trauma-induced defects, and dental implantology.

MD

Prof. Ullman is the Head of the Department of Plastic and Reconstructive Surgery and Burn Unit at Rambam Health Care Campus and runs the Aesthetic Plastic Surgery Service at the hospital. <read more> The main research interests of Prof. Ullman include burn wound healing, fat graft survival, lasers, and complicated traumas. In addition, Prof. Ullmann is a Senior Clinical Lecturer at the Rappaport Faculty of Medicine at the Technion.

Mr. Hoenlein served until 2022 as the Executive Vice Chairman/CEO of the Conference of Presidents of Major American Jewish Organizations, the coordinating body for 53 national Jewish organizations. He received his B.A. from Temple University and completed his doctoral course work at the University of Pennsylvania, where he taught International Relations and was a Middle East specialist at the Foreign Policy Research Institute. He was the Founding Executive Director of the JCRC of Greater New York and the Greater New York Conference on Soviet Jewry. Mr. Hoenlein appears regularly in the media, has three weekly U.S. national radio broadcasts, and has lectured and met leading officials worldwide. He has received numerous awards from the U.S. and foreign governments and institutions, including four Honorary Doctorates.

Mr. Ben Shoshan is the Managing Partner of the Southern Isreal Bridging Fund (SIBF). He has over 15 years of global experience in managing capital, as well as managing and mentoring startup companies. Mr. Ben Shoshan serves as chairman and member of the board of directors of several start-up companies and organizations, both profit and non-profit. Or was also a partner in Sherpa InnoVentures VC fund and is deeply involved in Israel’s venture capital industry.